Analysts Set AstraZeneca PLC (NASDAQ:AZN) Price Target at $89.75

Shares of AstraZeneca PLC (NASDAQ:AZN) have been given a consensus rating of “Buy” by the nine brokerages that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $89.75.

Several analysts have recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th.

Institutional Investors Weigh In On AstraZeneca

Institutional investors and hedge funds have recently bought and sold shares of the business. McClarren Financial Advisors Inc. increased its holdings in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca during the third quarter worth approximately $28,000. Ashton Thomas Securities LLC bought a new position in AstraZeneca in the 3rd quarter worth approximately $45,000. Albion Financial Group UT increased its position in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares during the period. Finally, Hollencrest Capital Management raised its stake in AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after acquiring an additional 192 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at $69.06 on Tuesday. The firm has a market cap of $214.16 billion, a P/E ratio of 33.04, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $87.68. The stock has a 50-day simple moving average of $66.44 and a 200-day simple moving average of $74.18.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 earnings per share. On average, equities analysts predict that AstraZeneca will post 4.12 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.